

cobas[®] HCV

Quantitative nucleic acid test

for use on the cobas[®] 4800 System

For in vitro diagnostic use

cobas[®] HCV	120 Tests	P/N: 06979602190
cobas[®] HBV/HCV/HIV-1 Control Kit	10 Sets	P/N: 06979572190
cobas[®] 4800 System Sample Preparation Kit 2	240 Tests 960 Tests	P/N: 06979513190 P/N: 06979521190
cobas[®] 4800 System Wash Buffer Kit	240 Tests 960 Tests	P/N: 05235863190 P/N: 05235871190
cobas[®] 4800 System Specimen Diluent 2	240 Tests	P/N: 06979556190
cobas[®] 4800 System Lysis Kit 2	240 Tests 960 Tests	P/N: 06979530190 P/N: 06979548190

TABLE OF CONTENTS

Intended use

Summary and explanation of the test

Background	4
Rationale for HCV testing.....	4
Explanation of the test	5
Principles of the procedure	5

Materials and reagents

Reagents.....	6
Reagent storage and handling requirements	14
Additional materials required	14
Instrumentation and software required but not provided	15
Supported sample tubes.....	15

Precautions and handling requirements

Warnings and precautions	16
Good laboratory practice.....	16
Reagent handling.....	17
Contamination.....	17
Integrity	17
Disposal	17
Spillage and cleaning.....	18
Sample collection, transport, and storage	18
Sample collection.....	18
Sample transport storage and stability	18

Instructions for use

Running the test.....	19
Sample processing volume	19
Run size.....	19
Workflow.....	20

Results

Quality control and validity of results	22
Control result interpretation.....	22
Interpretation of results.....	22
List of result flags.....	24
Procedural limitations	25

Non-clinical performance evaluation

Key performance characteristics	25
WHO International Standard.....	25
Linear range	27
Precision - within laboratory.....	29
Genotype verification	31
Specificity.....	32
Method correlation	34
Matrix equivalency – EDTA plasma versus serum.....	35
Whole system failure	36
Cross contamination.....	36

Clinical performance evaluation

Key performance characteristics	37
Clinical utility	37
Prediction of response to antiviral therapy	39
Comparison between cobas® 6800 and cobas® 8800 Systems – clinical utility	40
Diagnostic utility	41
Cross-reactivity in subjects with non-HCV related liver disease	43
Comparison between cobas® 6800 and cobas® 8800 Systems for diagnosis.....	46
Conclusion	46

Additional information

Key assay features	47
Symbols.....	48
Technical Support	49
Manufacturer	49
Trademarks and patents.....	49
Copyright.....	49
References.....	50
Document revision.....	52

Intended use

cobas® HCV is an in vitro nucleic acid amplification test for both the detection and quantitation of hepatitis C virus (HCV) RNA, in human EDTA plasma or serum, of HCV antibody positive or HCV-infected individuals. Specimens containing HCV genotypes 1 to 6 are validated for detection and quantitation in the assay.

cobas® HCV is intended for use as an aid in the diagnosis of HCV infection in the following populations: individuals with antibody evidence of HCV with evidence of liver disease, individuals suspected to be actively infected with HCV antibody evidence, and individuals at risk for HCV infection with antibodies to HCV. Detection of HCV RNA indicates that the virus is replicating and therefore is evidence of active infection.

cobas® HCV is intended for use as an aid in the management of HCV-infected patients undergoing anti-viral therapy. The assay can be used to measure HCV RNA levels at baseline, during treatment, at the end of treatment, and at the end of follow up of treatment to determine sustained or non-sustained viral response. The results must be interpreted within the context of all relevant clinical and laboratory findings.

cobas® HCV has not been approved for use as a screening test for the presence of HCV in blood or blood products.

Assay performance characteristics have been established for individuals treated with certain direct-acting antiviral agents (DAA) regimens. No information is available on the assay's predictive value when other DAA combination therapies are used.

Summary and explanation of the test

Background

HCV is considered to be the principal etiologic agent responsible for 90% to 95% of the cases of post-transfusion hepatitis.¹⁻⁴ HCV is a single-stranded, positive sense RNA virus with a genome of approximately 9,500 nucleotides coding for 3,000 amino acids. As a blood-borne virus, HCV can be transmitted by blood and blood products. Widespread adoption of HCV blood screening measures has markedly lowered the risk of transfusion-associated hepatitis. The incidence of HCV infection is highest in association with intravenous drug abuse and to a lesser extent with other percutaneous exposures.⁴

Quantitation of HCV RNA for measuring baseline viral loads and for on-treatment monitoring has been well established in demonstrating the efficacy of antiviral response to pegylated interferon plus ribavirin (pegIFN/RBV) combination therapy.⁵⁻⁹ Guidelines for the management and treatment of HCV^{10,11} recommend quantitative testing for HCV RNA before the start of antiviral therapy, at specified time intervals during therapy (response-guided therapy, RGT), and at 12 weeks or later, following the end of treatment.

Absence of detectable HCV RNA by a sensitive test, 12 weeks after the end of treatment, is the goal of treatment and indicates that a sustained virologic response (SVR) has been achieved.¹⁰

Determining the viral kinetics during therapy has been used to further personalize treatment duration with the more recently approved direct-acting antiviral agents (DAAs), the protease inhibitors telaprevir and boceprevir.¹²⁻¹⁵

Rationale for HCV testing

The presence of HCV antibodies indicates that a person has been infected with HCV. However, anti-HCV-positive status does not differentiate between acute, chronic, and resolved infection. Detection of HCV RNA in serum or plasma indicates ongoing viral replication and is therefore used to identify patients with persistent HCV infection.

With the expanding availability of very efficacious HCV-specific DAAs, including second-generation protease inhibitors, polymerase inhibitors, and NS5A inhibitors, and the very dynamic and extensive drug discovery pipeline for HCV

therapies, viral load monitoring remains the main laboratory test to confirm that SVR has been achieved with DAA-based treatment regimens.¹⁶⁻²¹

In summary, cobas® HCV is a quantitative test for HCV RNA detection, diagnosis of active infection and determination of viral kinetics, for use in laboratories that support clinical trials as well as routine clinical practice in the management of HCV patients.

Explanation of the test

cobas® HCV is a quantitative nucleic acid test performed on the cobas® 4800 System. cobas® HCV enables the detection and quantitation of HCV RNA in EDTA plasma or serum of infected patients. Dual probes are used to detect and quantify, but not discriminate HCV genotypes 1-6. The viral load is quantified against a non-HCV armored RNA quantitation standard (RNA QS), which is introduced into each sample during sample preparation. The RNA QS also functions as an internal control to monitor the entire sample preparation and PCR amplification process. In addition, the test utilizes three external controls: a high titer positive, a low titer positive, and a negative control.

Principles of the procedure

cobas® HCV is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 4800 System consists of the cobas® x 480 instrument and the cobas® z 480 analyzer. Automated data management is performed by the cobas® 4800 software which assigns test results for all tests as target not detected, < LLoQ (lower limit of quantitation), > ULoQ (upper limit of quantitation) or HCV RNA detected, a value in the linear range $LLoQ \leq x \leq ULoQ$. Results can be reviewed directly on the system screen, exported, or printed as a report.

Nucleic acids from patient samples, external controls and added armored RNA QS molecules are simultaneously extracted. In summary, viral nucleic acids are released by addition of proteinase and lysis reagent to the sample. The released nucleic acids bind to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured proteins, cellular debris and potential PCR inhibitors are removed with subsequent wash buffer steps and purified nucleic acids are eluted from the magnetic glass particles with elution buffer at elevated temperature.

Selective amplification of target nucleic acids from the patient sample is achieved by the use of target virus-specific forward and reverse primers which are selected from highly conserved regions of HCV. Selective amplification of RNA QS is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with the HCV genome. A thermostable DNA polymerase is used for both reverse-transcription and PCR amplification. The master mixes include deoxyuridine triphosphate (dUTP), instead of deoxythymidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).²²⁻²⁴ Any contaminating amplicons from previous PCR runs are inactivated as PCR templates by AmpErase, which is present in the master mixes, prior to the first denaturation step of PCR. AmpErase catalyzes the removal of uracil from DNA, but has no activity on RNA or naturally occurring DNA, which does not contain uracil. Amplicons formed during subsequent cycles of PCR are not inactivated since AmpErase is inactive at the annealing and denaturation temperatures of PCR.



cobas® HCV master mix contains dual detection probes specific for the HCV target sequences and one detection probe for the RNA QS. The probes are labeled with target-specific fluorescent reporter dyes allowing simultaneous detection of HCV target and RNA QS in two different detection channels.^{25,26} When not bound to the target sequence, the fluorescent signals of the intact probes are suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage of the probe by the 5'-to-3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Real-time detection and discrimination of PCR products is accomplished by measuring the fluorescence of the released reporter dyes for the viral targets and RNA QS.


Materials and reagents


Reagents


All unopened reagents and controls shall be stored as recommended in the Reagent storage and handling requirements table.


Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
cobas® HCV 120 Tests (P/N: 06979602190)	MMX R1 (cobas® Master Mix Reagent 1) Manganese acetate, potassium hydroxide, < 0.1% sodium azide	10 × 1.75 mL	N/A
	HCV MMX R2 (cobas® HCV Master Mix Reagent 2) Tricine buffer, potassium acetate, 18% dimethyl sulfoxide, glycerol, < 0.1% Tween 20, EDTA, < 0.12% dATP, dCTP, dGTP, dUTP, < 0.01% HCV primers, < 0.01% Quantitation Standard forward and reverse primers, < 0.01% fluorescent-labeled oligonucleotide probes specific for HCV and the Quantitation Standard, < 0.01% oligonucleotide aptamer, < 0.01% Z05D DNA polymerase (microbial), < 0.01% AmpErase (uracil-N-glycosylase) enzyme (microbial), < 0.1% sodium azide	10 × 0.5 mL	N/A
	RNA QS (cobas® RNA Quantitation Standard) Tris buffer, < 0.05% EDTA, < 0.001% non-HCV related armored RNA construct containing primer and probe specific sequence regions (non-infectious RNA in MS2 bacteriophage), < 0.1% sodium azide	10 × 1.75 mL	N/A


Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
cobas® HBV/HCV/HIV-1 Control Kit 10 Sets (P/N: 06979572190)	HBV/HCV/HIV-1 L(+)C (cobas® HBV/HCV/HIV-1 Low Positive Control) < 0.001% synthetic (armored) HIV-1 Group M RNA encapsulated in MS2 bacteriophage coat protein, < 0.001% synthetic (plasmid) HBV DNA encapsulated in Lambda bacteriophage coat protein, < 0.001% synthetic (armored) HCV RNA encapsulated in MS2 bacteriophage coat protein, normal human plasma, non-reactive by licensed tests for antibody to HIV 1/2, antibody to HCV, HBsAg, antibody to HBc; HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA not detectable by PCR methods. 0.1% ProClin® 300 preservative	10 × 0.75 mL	  <p>WARNING H317: May cause an allergic skin reaction. P261: Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/attention. P362 + P364: Take off contaminated clothing and wash it before reuse. P501: Dispose of contents/container to an approved waste disposal plant.</p>
	HBV/HCV/HIV-1 H(+)C (cobas® HBV/HCV/HIV-1 High Positive Control) < 0.001% synthetic (armored) HIV-1 Group M RNA encapsulated in MS2 bacteriophage coat protein, < 0.001% synthetic (plasmid) HBV DNA encapsulated in Lambda bacteriophage coat protein, < 0.001% synthetic (armored) HCV RNA encapsulated in MS2 bacteriophage coat protein, normal human plasma, non-reactive by licensed tests for antibody to HIV 1/2, antibody to HCV, HBsAg, antibody to HBc; HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA not detectable by PCR methods. 0.1% ProClin® 300 preservative	10 × 0.75 mL	55965-84-9 mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)
	(-) C (cobas® Negative Control) Normal human plasma, non-reactive by licensed tests for antibody to HIV 1/2, antibody to HCV, HBsAg, antibody to HBc; HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA not detectable by PCR methods. <0.1% ProClin® 300 preservative	10 × 0.75 mL	


Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
cobas® 4800 System Sample Preparation Kit 2 240 Tests (P/N: 06979513190)	MGP 2 (cobas® 4800 MGP Reagent 2) Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, <0.1% sodium azide	10 × 8 mL	N/A
	EB 2 (cobas® 4800 Elution Buffer 2) Tris buffer, 0.2% methyl-4 hydroxybenzoate	10 × 17 mL	
cobas® 4800 System Sample Preparation Kit 2 960 Tests (P/N: 06979521190)	MGP 2 (cobas® 4800 MGP Reagent 2) Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, <0.1% sodium azide	10 × 16 mL	N/A
	EB 2 (cobas® 4800 Elution Buffer 2) Tris buffer, 0.2% methyl-4 hydroxybenzoate	10 × 17 mL	
cobas® 4800 System Wash Buffer Kit 240 Tests (P/N: 05235863190)	WB Sodium citrate dihydrate, 0.05% N-Methylisothiazolone HCl ^b	10 × 55 mL	 <p>WARNING</p> <p>H317: May cause an allergic skin reaction. P261: Avoid breathing mist or vapours. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/ attention. P362 + P364: Take off contaminated clothing and wash it before reuse. P501: Dispose of contents/ container to an approved waste disposal plant. 26172-54-3 2-methyl-2H-isothiazol-3-one hydrochloride</p>

Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
cobas® 4800 System Wash Buffer Kit 960 Tests (P/N: 05235871190)	WB Sodium citrate dihydrate, 0.05% N-Methylisothiazolone HCl ^b	10 × 200 mL	 WARNING H317: May cause an allergic skin reaction. P261: Avoid breathing mist or vapours. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/ attention. P362 + P364: Take off contaminated clothing and wash it before reuse. P501: Dispose of contents/ container to an approved waste disposal plant. 26172-54-3 2-methyl-2H-isothiazol-3-one hydrochloride
cobas® 4800 System Specimen Diluent 2 240 Tests (P/N: 06979556190)	SD 2 Tris buffer, 0.1% methyl-4 hydroxybenzoate, <0.1% sodium azide	10 × 8 mL	N/A

Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
<p>cobas® 4800 System Lysis Kit 2 240 Tests (P/N: 06979530190)</p>	<p>P 2 (cobas® 4800 Protease 2) Tris buffer, <0.05% EDTA, calcium chloride, calcium acetate, 8% (w/v) proteinase^b</p>	<p>10 × 1.0 mL</p>	 <p>DANGER H317: May cause an allergic skin reaction. H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. P261: Avoid breathing mist or vapours. P280: Wear protective gloves. P284: Wear respiratory protection. P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor. 39450-01 -6 Proteinase, Tritirachium album serine</p>

Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
	<p>LYS 2 (cobas® 4800 Lysis Buffer 2) 43% (w/w) guanidine thiocyanate^b, 5% (w/v) polidocanol^b, 2% (w/v) dithiothreitol^b, dihydro sodium citrate</p>	10 × 27 mL	 <p>DANGER H302: Harmful if swallowed. H314: Causes severe skin burns and eye damage. H411: Toxic to aquatic life with long lasting effects. EUH032: Contact with acids liberates very toxic gas. EUH071: Corrosive to the respiratory tract. P273: Avoid release to the environment. P280: Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/ doctor. P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor. P391: Collect spillage. 593-84-0 Guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol</p>

Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
<p>cobas® 4800 System Lysis Kit 2 960 Tests (P/N: 06979548190)</p>	<p>P 2 (cobas® 4800 Protease 2) Tris buffer, <0.05% EDTA, calcium chloride, calcium acetate, 8% (w/v) proteinase^b</p>	<p>10 × 1.0 mL</p>	 <p>DANGER</p> <p>H317: May cause an allergic skin reaction. H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. P261: Avoid breathing mist or vapours. P280: Wear protective gloves. P284: Wear respiratory protection. P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor. 39450-01-6 Proteinase, Tritirachium album serine</p>

Kit	Components and Reagent Ingredients	Quantity per Kit	Safety Symbol and Warning ^a
	<p>LYS 2 (cobas® 4800 Lysis Buffer 2) 43% (w/w) guanidine thiocyanate^b, 5% (w/v) polidocanol^b, 2% (w/v) dithiothreitol^b, dihydro sodium citrate</p>	10 × 84 mL	 <p>DANGER</p> <p>H302: Harmful if swallowed.</p> <p>H314: Causes severe skin burns and eye damage.</p> <p>H411: Toxic to aquatic life with long lasting effects.</p> <p>EUH032: Contact with acids liberates very toxic gas.</p> <p>EUH071: Corrosive to the respiratory tract.</p> <p>P273: Avoid release to the environment.</p> <p>P280: Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.</p> <p>P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.</p> <p>P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/ doctor.</p> <p>P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.</p> <p>P391: Collect spillage.</p> <p>593-84-0 Guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol</p>

^a Product safety labeling primarily follows EU GHS guidance
Hazardous substance

Reagent storage and handling requirements

Reagent	Storage Temperature	Storage Time
cobas® HCV	2–8°C	Stable until the expiration date indicated
cobas® HBV/HCV/HIV-1 Control Kit	2–8°C	Stable until the expiration date indicated
cobas® 4800 System Sample Preparation Kit 2	2–8°C	Stable until the expiration date indicated
cobas® 4800 System Wash Buffer Kit	15–25°C	Stable until the expiration date indicated
cobas® 4800 System Specimen Diluent 2	2–8°C	Stable until the expiration date indicated
cobas® 4800 System Lysis Kit 2	2–8°C	Stable until the expiration date indicated

Do not freeze reagents.

Additional materials required

Materials	P/N
cobas® 4800 System Extraction (deepwell) Plate 2.0 mL	06884008001
cobas® 4800 System AD (microwell) Plate 0.3 mL	05232724001
Sealing foil applicator	04900383001
CORE Tips, 1000 µL, rack of 96	04639642001
200 mL Reagent Reservoir	05232759001
50 mL Reagent Reservoir	05232732001
24-position carrier	04639502001
32-position carrier	04639529001
Solid waste bag	05530873001 (small) or 04691989001 (large)
Hamilton STAR Plastic Chute	04639669001
Lab gloves, powderless	Any powderless disposable gloves are acceptable.
Vortex Mixer (single tube)	Any vortex mixer is acceptable.
Centrifuge equipped with a swinging bucket rotor with minimum RCF of 1500	Any appropriate centrifuge is acceptable.

For more information regarding the materials sold separately, contact your local Roche representative.

Instrumentation and software required but not provided

Required Instrumentation and Software, Not Provided
cobas® 4800 System cobas® x 480 instrument cobas® z 480 analyzer Control Unit
cobas® 4800 System Application Software (Core) Version 2.2.0 or higher
cobas® 4800 System cobas® HCV AP v1.1.0 or higher

Note: Contact your local Roche representative for a detailed order list for sample racks, tip racks, reagent racks and plate carriers accepted on the instruments.

Supported sample tubes

The test accepts commonly used primary and secondary tubes.

The following sample tubes are supported:

Primary tubes

Nominal Diameter (mm)	Sample input volume – processed (centrifuged) whole blood		Tube Additive	
	400 µL processing volume	200 µL processing volume	EDTA Plasma	Serum
11-14	1800 µL or more	1000 µL or more	With or without gel	With gel
14.5-16	More than 4000 µL	More than 4000 µL	With or without gel	With gel

For specific sample tube order information, and minimum sample input volumes for specific primary tubes, contact your local Roche representative.

Secondary tubes

Nominal Diameter (mm)	Sample input volume	
	400 µL processing volume	200 µL processing volume
11-16	1000 µL or more (specific secondary tubes have a minimum input volume of less than 1000 µL)	750 µL or more (specific secondary tubes have a minimum input volume of less than 750 µL)

For specific sample tube order information, and minimum sample input volumes for specific secondary tubes, contact your local Roche representative.

Precautions and handling requirements

Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high analytical sensitivity of this test, care should be taken to keep reagents, samples and amplification mixtures free of contamination.

- For in vitro diagnostic use only.
- **cobas® HCV** has not been evaluated for use as a screening test for the presence of HCV in blood or blood products.
- All patient samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29-A4.^{27,28} Only personnel proficient in handling biohazardous materials and the use of **cobas® HCV** and the **cobas® 4800 System** should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions.
- **cobas® HBV/HCV/HIV-1 Control Kit** contains plasma derived from human blood. The source material has been tested by a licensed antibody test and found to be non-reactive for the presence of antibody to HCV, antibody to HIV-1/2, HBsAg and antibody to HBc. Testing by PCR methods showed no detectable HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA. No known test method can offer complete assurance that products derived from human blood will not transmit infectious agents.
- Prevent exposure of MGP to sources of magnetic field.
- **Do not freeze whole blood or any samples stored in primary tubes.**
- Use only supplied or specified required consumables to ensure optimal test performance.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect optimal test performance.
- False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.
- For additional warnings, precautions and procedures to reduce the risk of contamination for the **cobas® x 480** instrument or **cobas® z 480** analyzer, consult the **cobas® 4800 System – User Assistance**. If contamination is suspected, perform cleaning and weekly maintenance as described in the **cobas® 4800 System – User Assistance**.

Note: For specific instructions, see “*Sample collection, transport, and storage*”.

Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink or smoke in laboratory work areas.
- Wash hands thoroughly after handling samples and kit reagents, and after removing the lab gloves.
- Wear eye protection, lab coats and lab gloves when handling any reagents. Avoid contact of these materials with the skin, eyes or mucous membranes. If contact does occur, immediately wash with large amounts of water. Burns can occur if left untreated. If spills occur, dilute with water before wiping dry.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10). Follow by wiping the surface with 70% ethanol.
- Maintain a consistent temperature in the laboratory that conforms to the environmental specifications of the system, as provided in the **cobas® 4800 System - User Assistance**.

Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples or controls.
- Before use, visually inspect each reagent bottle and vial to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas® 4800 Lysis Buffer 2** contains guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- **cobas® HCV**, **cobas® 4800 Sample Preparation Kit 2** and **cobas® 4800 System Specimen Diluent 2** contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Do not allow **cobas® 4800 Lysis Buffer 2**, which contains guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. This mixture can produce a highly toxic gas.

Contamination

- Lab gloves must be worn and must be changed between handling samples and **cobas® HCV** reagents to prevent contamination. Avoid contaminating gloves when handling specimens and controls. Wear lab gloves, lab coats, and eye protection when handling samples and kit reagents.
- Avoid microbial and ribonuclease contamination of reagents.
- False positive results may occur if carryover of samples is not prevented during sample handling.

Integrity

- Do not use kits after their expiry dates.
- Do not pool reagents.
- Do not use disposable items after their expiry dates.
- All disposable items are for one time use. Do not reuse.
- All equipment should be properly maintained according to the manufacturer's instructions.

Disposal

- **cobas® HCV**, **cobas® 4800 System Sample Preparation Kit 2** and **cobas® 4800 System Specimen Diluent 2** contain sodium azide (see “**Warnings and precautions**”). Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. While disposing of solutions containing sodium azide down laboratory sinks, flush the drains with a large volume of cold water to prevent azide buildup.
- Dispose of unused reagents and waste in accordance with country, federal, state and local regulations.

Note: *For disposal of liquid waste, refer to the cobas® 4800 System – User Assistance.*

Spillage and cleaning

- **cobas**® 4800 Lysis Buffer 2 contains guanidine thiocyanate. If liquid containing guanidine thiocyanate is spilled, clean with suitable laboratory detergent and water. If the spilled liquid contains potentially infectious agents, FIRST clean the affected area with laboratory detergent and water, and then with 0.5% sodium hypochlorite.
- If spills occur on the **cobas**® x 480 instrument, follow the instructions in the **cobas**® 4800 System – User Assistance to clean.
- Do not use sodium hypochlorite solution (bleach) for cleaning the **cobas**® x 480 instrument or the **cobas**® z 480 analyzer. Clean the **cobas**® x 480 instrument or the **cobas**® z 480 analyzer according to procedures described in the **cobas**® 4800 System – User Assistance.

Sample collection, transport, and storage

Note: Handle all specimens as if they are capable of transmitting infectious agents.

Store all samples at specified temperatures.

Sample stability is affected by elevated temperatures.

If using frozen samples in secondary tubes, place the samples at room temperature (15-30°C) until completely thawed and then briefly mix (e.g., vortex for 3-5 seconds) and centrifuge to collect all sample volume at the bottom of the tube.

Sample collection

Blood should be collected in SST™ Serum Separation Tubes, BD Vacutainer® PPT™ Plasma Preparation Tubes for Molecular Diagnostic Test Methods or in sterile tubes using EDTA as the anticoagulant.

Note: The user must follow the guidance provided by the tube manufacturer for serum/plasma preparation.

Sample transport storage and stability

- Whole blood collected in SST™ Serum Separation Tubes, BD Vacutainer® PPT™ Plasma Preparation Tubes for Molecular Diagnostic Test Methods or in sterile tubes using EDTA as the anticoagulant may be stored and/or transported for up to 24 hours at 2°C to 25°C prior to plasma/serum preparation and subsequent testing.
- Plasma/serum samples may be stored in secondary tubes for up to 24 hours at 2°C to 25°C, up to 72 hours at 2°C to 8°C or up to 6 weeks at $\leq -18^{\circ}\text{C}$. Separated plasma/serum samples in secondary tubes are stable for up to three freeze/thaw cycles when stored frozen at $\leq -18^{\circ}\text{C}$.
- If samples are to be shipped, they should be packaged and labeled in compliance with applicable country and/or international regulations covering the transport of samples and etiologic agents.

Instructions for use

Running the test

Sample processing volume

The default sample processing volume for **cobas**® HCV is 400 µL. For low volume samples, a sample processing volume of 200 µL may be chosen. Only in this case, **cobas**® 4800 System Specimen Diluent 2 as an additional reagent has to be loaded onto the system. The user will be prompted to do so by the software wizard, if the sample type “Diluted serum or plasma” was chosen during the work order creation.

Figure 1: **cobas**® HCV workflow

1	Start the system
2	Perform instrument maintenance
3	Remove samples and reagents from storage
4	Start run
5	Scan parameter cards
6	Load samples
7	With LIS: confirm work order Without LIS: create work order
8	Load consumables (deepwell plate, microwell plate, tip racks)
9	Load reagents
10	Start sample preparation run
11	Unload and seal microwell plate
12	Load microwell plate into analyzer
13	Remove samples, used reagents, and deepwell plate
14	Review results
15	With LIS: send results to LIS
16	Unload analyzer

Note: Refer to the **cobas**® 4800 System - User Assistance for detailed operating instructions.

Run size

The generic sample preparation reagents (**cobas**® 4800 System Sample Preparation Kit 2, **cobas**® 4800 System Lysis Kit 2 and **cobas**® 4800 System Wash Buffer Kit) are available in two kit sizes, each sufficient for 10 runs of up to either 24 or 96 samples, which include the controls and samples to be run. **cobas**® HCV is available in a single kit size sufficient to test up to 120 (10×12) samples, including controls and samples. The **cobas**® HBV/HCV/HIV-1 Control Kit is available in a single kit size and can support all run configurations. For each test batch, one HBV/HCV/HIV-1 Low Positive Control, one HBV/HCV/HIV-1 High Positive Control and one Negative Control must be used. For a single test run, the maximum number of samples allowed is 93 samples and 3 controls. Figure 1 summarizes the procedure.

Note: For optimal use of reagents, the generic sample preparation reagents can be used for a run containing 1-21 total samples (10×24 test kit size) or 1-93 total samples (10×96 test kit size). However, different kit sizes of the cobas® 4800 System Wash Buffer Kit, cobas® 4800 System Sample Preparation Kit 2 and cobas® 4800 System Lysis Kit 2 cannot be combined. For example, if a 96-test Wash Buffer reagent bottle is scanned at the start of the run, 96-test size reagents from the other sample preparation reagent kits must also be used.

Workflow

cobas® HCV is performed using the full workflow within the cobas® 4800 Software. It consists of sample preparation on the cobas® x 480 instrument followed by amplification/detection on the cobas® z 480 analyzer. cobas® HCV may be performed alone, or in mixed-batch mode with tests that share the same automated sample extraction process and PCR profile for amplification and detection. At the test selection step the software will display tests that are compatible with cobas® HCV for mixed-batch mode. Refer to the cobas® 4800 System - User Assistance for details.

1. Perform the system startup by following the instructions in the cobas® 4800 System - User Assistance.
2. Perform maintenance actions by following the instructions in the cobas® 4800 System - User Assistance.
3. Collect all reagents and consumables needed. All reagents except HCV MMX R2 and MMX R1 must be at ambient temperature prior to loading on the cobas® x 480 instrument. The HCV MMX R2 and MMX R1 reagents may be taken directly from 2-8°C storage as they equilibrate to ambient temperature on board the cobas® x 480 instrument by the time they are used in the process.

Note: All reagents and reagent reservoirs are barcoded and designed for one time use. The cobas® 4800 Software tracks the use of the reagents and reagent reservoirs and rejects previously used reagents or reagent reservoirs.

4. Start a new run and select the workflow type as HCV. To perform a mixed batch run, select other applicable workflow types (i.e., HIV-1, CMV or HCV GT) in addition to HCV.
5. Follow the software wizard guide and scan the barcode on the control ranges and calibration coefficients parameter cards.

Note: Scan parameter cards from unexpired reagents. The software does not surveil reagent expiry dates in parameter cards. Check the expiry date printed in the parameter card or in the reagent kits before scanning the corresponding barcode ID.

6. Load the samples. Primary or secondary sample tubes can be loaded and minimum sample volume depends on the tube type and size. Refer to the supported sample tubes section for more details
7. Create the work order. There are three ways to create a work order:
 - By using the sample editor before the sample rack is loaded into the cobas® x 480 instrument (“Editor” button on the right of the main menu). Work orders can be saved, edited and reloaded if necessary. When selecting the requested results, select “HCV”.
 - By following the software wizard for the new run and loading samples into cobas® x 480 instrument when prompted. The sample barcodes will be automatically scanned, and the requested results for each sample must be defined. When selecting the requested results, select “HCV”.
 - By using your institution’s LIS system.

Refer to the cobas® 4800 System - User Assistance for more details. Load samples and define/select work order or use LIS as appropriate.

8. Load consumables as instructed by the software wizard. Do not load or remove individual tips into a partially used tip rack, as the software tracks the number of tips that are left. If there are not enough tips for the run to be conducted, the software will alert the user.

9. Load the reagents.

Load the sample preparation reagents into the barcoded reagent reservoirs. The reagent reservoirs are available in two sizes: 200 mL and 50 mL. Follow the software wizard guide to select the correct reagent reservoir size. The reagent reservoir barcodes must face to the right of the carrier. Use the “scan-scan-pour-place” method to load sample preparation reagents:

- Scan the reagent bottle barcode
- Scan the reagent reservoir barcode
- Pour the reagent into the reservoir
- Place the filled reagent reservoir into the designated position on the reagent carrier

Note: *The cobas® 4800 System has an internal clock to monitor the length of time the reagents are on-board. Once LYS 2 or WB is scanned, 1 hour is allowed to complete the loading process and click on the Start button. A countdown timer is displayed on the Workplace Tab. The system will not allow the run to start if the on-board timer has expired.*

Note: *To assure the accurate transfer of MGP, vortex or vigorously shake the MGP vial immediately prior to dispensing into the reagent reservoir.*

10. Load amplification/detection reagent vials (HCV MMX R2, MMX R1 and RNA QS), control vials [HBV/HCV/HIV-1 L(+)C, HBV/HCV/HIV-1 H(+)C and (-) C] and generic reagent vials (P2 and SD2 as required) directly onto the reagent carrier.

Note: *In order to prevent unnecessary run aborts and contamination, it is required to flick down the reagent vials to avoid formation of bubbles/liquid films. Controls should be opened starting with the ones closest to you (from position 24 to 1). Change lab gloves after handling positive controls.*

11. Start the sample preparation run. After a successful sample preparation run, the “Sample Preparation results” button and the Unload button become available. If desired, select “Sample Preparation results” button to review the results then select “Unload” to unload the plate carriers. Alternatively, select “Unload” to unload the plate carrier without reviewing the results. See the cobas® 4800 System - User Assistance.
12. After unloading the microwell plate, follow the instructions in the cobas® 4800 System - User Assistance for sealing and transferring the plate to the cobas® z 480 analyzer.
13. Load the microwell plate into the analyzer and start the amplification and detection run as instructed in the cobas® 4800 System - User Assistance.

Note: *The cobas® 4800 System has an internal clock to monitor the length of time after addition of the prepared samples to activated master mix. Amplification and detection should be started as soon as possible but no later than 40 minutes after the end of the cobas® x 480 instrument run. A countdown timer is displayed on the Workplace Tab. The system aborts the run if the timer has expired.*

14. Remove samples, used reagents and deepwell plate as instructed in the cobas® 4800 System - User Assistance.
15. After the amplification and detection run is completed, follow the instructions in the cobas® 4800 System - User Assistance to review and accept results.
16. If working with LIS, send results to the LIS.
17. Follow the instructions in the cobas® 4800 System - User Assistance to unload the microwell plate from the cobas® z 480 analyzer.

Results

The cobas® 4800 System automatically determines the HCV RNA concentration for the samples and controls. The HCV RNA concentration is expressed in International Units per milliliter (IU/mL).

Quality control and validity of results

- One negative control (-) C and two positive controls, a low positive control HBV/HCV/HIV-1 L(+)C and a high positive control HBV/HCV/HIV-1 H(+)C, are processed with each batch.
- In the cobas® 4800 Software and/or report, check for batch validity.
- Invalidation of results is performed automatically by the cobas® 4800 Software based on negative and positive control failures.

Control result interpretation

Table 1: Control result interpretation for negative and positive controls

Negative Control	Result	Interpretation
(-) C	Target Not Detected	Control is valid. HCV RNA not detected.
	Invalid	An invalid result or the calculated titer result for the negative control is not negative.
Positive Control	Result	Interpretation
HBV/HCV/HIV-1 L(+)C	Titer	Control is valid. Calculated titer is within the control range.
	Invalid	An invalid result or the calculated titer result for the low positive control is not within the assigned range.
HBV/HCV/HIV-1 H(+)C	Titer	Control is valid. Calculated titer is within the control range.
	Invalid	An invalid result or the calculated titer result for the high positive control is not within the assigned range.

Interpretation of results

Note: All assay and batch validation is determined by the cobas® 4800 Software.

Note: A valid batch may include both valid and invalid sample results.

For a valid batch, sample results are interpreted as shown in Table 2.

Table 2: Individual target result interpretation

Result Read-Out from cobas® 4800 System	Analytical Interpretation	Clinical Interpretation
Target Not Detected	HCV RNA not detected. Report results as “HCV not detected.”	No current HCV infection For HCV Diagnosis: No further testing indicated.* For Viral Load Assessment: Routine clinical follow-up according to national HCV guidelines.
< Titer Min	HCV RNA detected but not quantified. Calculated titer is below the Lower Limit of Quantitation (LLoQ) of the assay. Report results as “HCV detected, less than (Titer Min)” Titer min = 1.50E+01 IU/mL (400 µL) Titer min = 2.50E+01 IU/mL (200 µL)	Low-level HCV viremia, may indicate previous spontaneous or treatment-related resolution of HCV infection. For HCV Diagnosis: Results must be interpreted within the context of all relevant clinical and laboratory findings.* For Viral Load Assessment: Routine clinical follow-up according to national HCV guidelines.
15 IU/mL ≤ Titer < 25 IU/mL (400 µL)	HCV RNA detected and quantified. Calculated titer is within the Linear Range of the assay – greater than or equal to 15 IU/mL and less than 25 IU/mL. Report results as “(Titer) of HCV detected”.	Low-level HCV viremia, may indicate previous spontaneous or treatment-related resolution of HCV infection.* For HCV Diagnosis and Viral Load Assessment: Provide patient with appropriate counseling and link to care and treatment according to current national HCV treatment guidelines.
25 IU/mL ≤ Titer ≤ Titer Max	HCV RNA detected and quantified Calculated titer is within the Linear Range of the assay – greater than or equal to 25 IU/mL and less than or equal to Titer Max. Report results as “(Titer) of HCV detected”.	Current HCV Infection. For HCV Diagnosis and Viral Load Assessment: Provide patient with appropriate counseling and link to care and treatment according to current national HCV treatment guidelines.
> Titer Max ^a	Calculated titer is above the Upper Limit of Quantitation (ULoQ) of the assay. Report results as “HCV detected, greater than (Titer Max).” Titer max = 1.00E+08 IU/mL	Current HCV Infection. For HCV Diagnosis and Viral Load Assessment: Provide patient with appropriate counseling and link to care and treatment according to current national HCV treatment guidelines.

* Repeat HCV RNA testing if the person tested is suspected to have had HCV exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.

^a Sample result > Titer Max refers to HCV positive samples detected with titers above the upper limit of quantitation (ULoQ). If a quantitative result is desired, the original sample should be diluted with HCV-negative EDTA plasma or serum, depending on the type of the original sample, and the test should be repeated. Multiply the reported result by the dilution factor.

List of result flags

The following table lists all flags which are relevant for result interpretation.

Table 3: List of flags

Flag code	Description	Recommended action
R4800	The target is invalid due to calculation failure.	The target is invalid due to calculation failure. 1. Rerun the sample. 2. If the problem persists, contact Roche Service.
R4801	The quantitation standard is invalid.	The quantitation standard is invalid for a sample. 1. Rerun the sample. 2. If the problem persists, contact Roche Service.
R4802	An external control is invalid.	An external control is invalid. ^a 1. Repeat entire run with fresh reagents. 2. If the problem persists, contact Roche Service.
R4803	The quantitation standard is invalid.	The quantitation standard is invalid for an external control. 1. Repeat entire run with fresh reagents. 2. If the problem persists, contact Roche Service.
R4804	The external control is out of range.	The external control is out of range. ^b 1. Repeat entire run with fresh reagents. 2. If the problem persists, contact Roche Service.
X3	Error: Clot was detected Sample was not processed.	Make sure that the samples were handled according to the workflow description. 1. Check the sample for clots. 2. Rerun the sample.
X4	Error: Pipetting error occurred. Sample was not processed.	Insufficient sample volume or mechanical error during pipetting is the most likely reason. 1. Make sure that there is enough sample volume. 2. Check whether the tip eject plate is placed correctly. 3. Rerun the sample.

^a This is a sample flag and it occurs when an external control in the run is called invalid.

^b This flag includes all scenarios in which the external control is invalid (target calling or titer).

Note: For all system flags refer to the cobas® 4800 System – User Assistance.

Procedural limitations

1. **cobas**® HCV has been evaluated only for use in combination with the **cobas**® HBV/HCV/HIV-1 Control Kit, **cobas**® 4800 System Sample Preparation Kit 2, **cobas**® 4800 System Lysis Kit 2, **cobas**® 4800 System Wash Buffer Kit and **cobas**® 4800 System Specimen Diluent 2.
2. Reliable results are dependent on adequate sample collection, transport, storage and processing. Follow the procedures in this Instructions-For-Use document (also referred to as a Package Insert) and the **cobas**® 4800 System - User Assistance.
3. This test has been validated only for use with EDTA plasma and serum. Testing of other sample types may result in inaccurate results.
4. Quantitation of HCV RNA is dependent on the number of virus particles present in the samples and may be affected by sample collection methods, patient factors (i.e., age, presence of symptoms), and/or stage of infection.
5. Though rare, mutations within the highly conserved regions of a viral genome covered by **cobas**® HCV may affect primers and/or probe binding resulting in the under-quantitation of virus or failure to detect the presence of virus.
6. The predictive value of an assay depends on the prevalence of the disease in any particular population.
7. The addition of AmpErase enzyme into the **cobas**® HCV Master Mix enables selective amplification of target nucleic acid; however, good laboratory practices and careful adherence to the procedures specified in this Instructions-For-Use document are necessary to avoid contamination of reagents and amplification mixtures.
8. Use of this product must be limited to personnel trained in the techniques of PCR and the use of the **cobas**® 4800 System.
9. Only the **cobas**® x 480 instrument and **cobas**® z 480 analyzer have been validated for use with this product. No other sample preparation instrument or PCR System can be used with this product.
10. Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. Users should follow their own specific policies/procedures.
11. Cross-contamination can cause false positive results. The sample to sample cross-contamination rate of **cobas**® HCV has been determined in a non-clinical study to be 0.0%. Run to run cross-contamination has not been observed.
12. **cobas**® HCV is not intended for use as a screening test for the presence of HCV in blood or blood products.

Non-clinical performance evaluation

Key performance characteristics

Limit of Detection (LoD)

WHO International Standard

The limit of detection of **cobas**® HCV was determined by analysis of serial dilutions of the WHO International Standard for HCV RNA for Nucleic Acid Amplification Technology Assays (4th WHO International Standard) genotype 1a obtained from NIBSC, in HCV-negative EDTA plasma or serum using sample processing volumes of 400 µL and 200 µL. Panels of six concentration levels plus a negative were tested over three lots of the **cobas**® HCV reagents, multiple runs, days, operators, and instruments.

The results for EDTA plasma and serum from both sample processing volumes are shown in Table 4 to Table 7. The study demonstrates that **cobas**® HCV detected HCV RNA at a concentration of 9.2 IU/mL in EDTA plasma and 7.6 IU/mL in serum with a hit rate of $\geq 95\%$ by PROBIT for the 400 μL sample processing volume and at a concentration of 15.2 IU/mL in EDTA plasma and 15.3 IU/mL in serum with a hit rate of $\geq 95\%$ by PROBIT for the 200 μL sample processing volume.

Table 4: Limit of detection in EDTA plasma (400 μL)

Input titer concentration (HCV RNA IU/mL)	Number of valid replicates	Number of positives	Hit rate
42.0	125	125	100.0%
21.0	124	124	100.0%
15.0	125	123	98.4%
9.0	124	117	94.4%
5.0	126	103	81.8%
3.0	125	80	64.0%
0.0	36	0	0.0%
LoD by PROBIT at 95% hit rate	9.2 IU/mL 95% confidence range: 7.8–11.5 IU/mL		

Table 5: Limit of detection in serum (400 μL)

Input titer concentration (HCV RNA IU/mL)	Number of valid replicates	Number of positives	Hit rate
42.0	125	125	100.0%
21.0	126	126	100.0%
15.0	126	126	100.0%
9.0	126	120	95.2%
5.0	126	110	87.3%
3.0	126	86	68.3%
0.0	36	0	0.0%
LoD by PROBIT at 95% hit rate	7.6 IU/mL 95% confidence range: 6.5–9.5 IU/mL		

Table 6: Limit of detection in EDTA plasma (200 µL)

Input titer concentration (HCV RNA IU/mL)	Number of valid replicates	Number of positives	Hit rate
60.0	126	126	100.0%
45.0	125	125	100.0%
25.0	125	125	100.0%
18.0	124	119	96.0%
10.0	126	106	84.1%
5.0	124	69	55.7%
0.0	36	0	0.0%
LoD by PROBIT at 95% hit rate	15.2 IU/mL 95% confidence range: 13.1–18.5 IU/mL		

Table 7: Limit of detection in serum (200 µL)

Input titer concentration (HCV RNA IU/mL)	Number of valid replicates	Number of positives	Hit rate
60.0	126	126	100.0%
45.0	126	126	100.0%
25.0	126	123	97.6%
18.0	126	125	99.2%
10.0	126	106	84.1%
5.0	125	73	58.4%
0.0	36	0	0.0%
LoD by PROBIT at 95% hit rate	15.3 IU/mL 95% confidence range: 13.1–18.7 IU/mL		

Linear range

Linearity of cobas® HCV was determined by analysis with a dilution series consisting of 13 panel members with the predominant HCV genotype (GT 1a) spanning the assay linear range. High titer panel members were prepared from a high titer armored RNA (arRNA) stock whereas the lower titer panel members were prepared from clinical sample (CS). The linearity panel was designed to have an approximately two log₁₀ titer overlap between the two material sources.

With 400 µL sample processing volume, cobas® HCV is linear for EDTA plasma and serum from 15.0 IU/mL to 1.0E+08 IU/mL and shows a maximum deviation from the better fitting non-linear regression of less than ±0.08 log₁₀. Across the linear range, the accuracy of the test was within ±0.20 log₁₀ for EDTA plasma and within ±0.23 log₁₀ for serum.

With 200 µL sample processing volume, cobas® HCV is linear for EDTA plasma and serum from 25 IU/mL to 1.0E+08 IU/mL and shows a maximum deviation from the better fitting non-linear regression of less than ±0.09 log₁₀. Across the linear range, the accuracy of the test was within ±0.20 log₁₀ for EDTA plasma and within ±0.25 log₁₀ for serum.

See Figure 2 to Figure 5 for representative results.





Figure 2: Linearity in EDTA plasma (400 µL)**Figure 3:** Linearity in serum (400 µL)

Figure 4: Linearity in EDTA plasma (200 µL)**Figure 5:** Linearity in serum (200 µL)

Precision - within laboratory

Precision of **cobas**® HCV was determined by analysis of serial dilutions of clinical HCV (Genotype 1a) samples (CS) and of armored RNA HCV (arRNA) in HCV-negative EDTA plasma and serum. Five dilution levels were tested in 72 replicates for each level, matrix and sample processing volume across three lots of **cobas**® HCV reagents using two instruments and three operators over 12 days. Each sample was carried through the entire **cobas**® HCV procedure on the **cobas**® 4800 System. Therefore, the precision reported here represents all aspects of the test procedure. The results are shown in Table 8 to Table 11.

cobas® HCV showed high precision for three lots of reagents tested across a concentration range of 1.0E+03 IU/mL to 1.0E+08 IU/mL with both 200 µL and 400 µL sample processing volumes.

Table 8: Within laboratory precision of cobas® HCV (EDTA plasma samples – sample processing volume of 400 µL)*

Nominal concentration (IU/mL)	Assigned concentration (IU/mL)	Source material	EDTA plasma			
			Lot 1	Lot 2	Lot 3	All Lots
			SD	SD	SD	Pooled SD
1.0E+08	8.5E+07	arRNA	0.05	0.06	0.05	0.06
1.0E+07	8.5E+06	arRNA	0.06	0.06	0.06	0.06
4.0E+05	3.4E+05	arRNA	0.06	0.05	0.06	0.06
1.0E+04	9.9E+03	CS	0.10	0.10	0.10	0.10
1.0E+03	9.9E+02	CS	0.09	0.08	0.07	0.08

* Titer data are considered to be log-normally distributed and are analyzed following log₁₀ transformation. Standard deviation (SD) columns present the total of the log-transformed titer for each of the three reagent lots.

Table 9: Within-laboratory precision of cobas® HCV (serum samples – sample processing volume of 400 µL)*

Nominal concentration (IU/mL)	Assigned concentration (IU/mL)	Source material	Serum			
			Lot 1	Lot 2	Lot 3	All Lots
			SD	SD	SD	Pooled SD
1.0E+08	6.5E+07	arRNA	0.07	0.12	0.14	0.12
1.0E+07	6.5E+06	arRNA	0.07	0.07	0.09	0.08
4.0E+05	2.6E+05	arRNA	0.07	0.06	0.07	0.07
1.0E+04	7.9E+03	CS	0.07	0.05	0.08	0.07
1.0E+03	7.9E+02	CS	0.07	0.05	0.06	0.06

* Titer data are considered to be log-normally distributed and are analyzed following log₁₀ transformation. Standard deviation (SD) columns present the total of the log-transformed titer for each of the three reagent lots.

Table 10: Within-laboratory precision of cobas® HCV (EDTA plasma – sample processing volume of 200 µL)*

Nominal concentration (IU/mL)	Assigned concentration (IU/mL)	Source material	EDTA plasma			
			Lot 1	Lot 2	Lot 3	All Lots
			SD	SD	SD	Pooled SD
1.0E+08	8.5E+07	arRNA	0.07	0.09	0.06	0.07
1.0E+07	8.5E+06	arRNA	0.05	0.05	0.05	0.05
4.0E+05	3.4E+05	arRNA	0.04	0.05	0.07	0.05
1.0E+04	9.9E+03	CS	0.06	0.06	0.07	0.06
1.0E+03	9.9E+02	CS	0.06	0.07	0.05	0.06

* Titer data are considered to be log-normally distributed and are analyzed following log₁₀ transformation. Standard deviation (SD) columns present the total of the log-transformed titer for each of the three reagent lots.

Table 11: Within laboratory precision of cobas® HCV (serum – sample processing volume of 200 µL)*

Nominal concentration (IU/mL)	Assigned concentration (IU/mL)	Source material	Serum			
			Lot 1	Lot 2	Lot 3	All Lots
			SD	SD	SD	Pooled SD
1.0E+08	6.5E+07	arRNA	0.05	0.06	0.06	0.06
1.0E+07	6.5E+06	arRNA	0.07	0.07	0.05	0.06
4.0E+05	2.6E+05	arRNA	0.08	0.05	0.07	0.07
1.0E+04	7.9E+03	CS	0.04	0.04	0.04	0.04
1.0E+03	7.9E+02	CS	0.04	0.06	0.05	0.05

* Titer data are considered to be log-normally distributed and are analyzed following \log_{10} transformation. Standard deviation (SD) columns present the total of the log-transformed titer for each of the three reagent lots.

Genotype verification

The performance of cobas® HCV on HCV genotypes was evaluated by:

- Verification of the limit of detection for genotypes 1b through 6
- Verification of the linearity for genotypes 1b through 6
- Titer assignment was performed using cobas® HCV.

Verification of limit of detection for genotypes 1b through 6

HCV RNA clinical specimens for six different genotypes (1b, 2, 3, 4, 5, 6) were diluted in EDTA plasma and serum to the EDTA plasma LOD concentration of the predominant genotype (HCV GT 1a) based on 95% Hit Rate LoD analysis (15.0 IU/mL). Hit rate analysis was performed with 42 replicates for each genotype and sample matrix. These results verify that cobas® HCV detected HCV for HCV genotypes 1b, 2, 3, 4, 5, and 6 at the concentration of 15 IU/mL with an upper one-sided 95% confidence interval being greater to the expected hit rate of 95%.

Table 12: LoD verification of HCV genotypes 1b-6 in 400 µL EDTA plasma

Genotype	Hit rate	Upper One Sided 95% Confidence Interval
GT 1b	95.2%	99.1%
GT 2	100.0%	100.0%
GT 3	100.0%	100.0%
GT 4	100.0%	100.0%
GT 5	100.0%	100.0%
GT 6	97.6%	99.9%

Table 13: LoD verification of HCV genotypes 1b-6 in 400 µL in serum

Genotype	Hit rate	Upper One Sided 95% Confidence Interval
GT 1b	100.0%	100.0%
GT 2	100.0%	100.0%
GT 3	100.0%	100.0%
GT 4	100.0%	100.0%
GT 5	100.0%	100.0%
GT 6	100.0%	100.0%

Verification of linear range for genotypes 1b through 6

The dilution series used in the verification of genotypes linearity study of cobas® HCV consists of nine panel members spanning the intended linear range. High titer panel members were prepared from a high titer arRNA stock whereas the lower titer panel members were made from a high titer clinical sample (CS). The linearity panel was designed to have a minimum overlap of 2 log₁₀ titer between the two material sources. The linear range of cobas® HCV spanned from the LLoQ (15.0 IU/mL for a sample processing volume of 400 µL) to the ULoQ (1.0E+08 IU/mL) and included at least two medical decision points. Twelve replicates per level were tested in EDTA plasma.

The linear range of cobas® HCV was verified for all six genotypes (1b, 2, 3, 4, 5, and 6). The maximum deviation between the linear regression and the better fitting non-linear regression was equal to or less than 0.14 log₁₀.

Specificity

The specificity of cobas® HCV was determined by analyzing HCV-negative EDTA plasma and serum samples from individual donors. Six hundred twelve individual EDTA plasma and 613 individual serum samples (1225 total results) were tested with three lots of cobas® HCV reagents. Six hundred nine samples in EDTA plasma and 613 samples in serum tested negative for HCV RNA. In the test panel, the specificity of cobas® HCV was 99.5% in plasma (95% confidence limit: ≥ 98.7%) and 100.0% (95% confidence limit: ≥ 99.5%) in serum.

Analytical specificity

The analytical specificity of cobas® HCV was evaluated by diluting a panel of pathogens (Table 14) with HCV RNA positive and HCV RNA negative EDTA plasma. The pathogens were added to negative EDTA plasma and tested with and without HCV RNA. Negative results were obtained with cobas® HCV for all pathogen samples without HCV target and positive results were obtained on all of the pathogen samples with HCV target. Furthermore, the mean log₁₀ titer of each of the positive HCV samples containing potentially cross-reacting organisms was within ± 0.09 log₁₀ of the mean log₁₀ titer of the respective positive spike control.

Table 14: Pathogens tested for cross-reactivity

Viruses		Bacteria	Yeast
Adenovirus type 5	Herpes Simplex Virus type 1 and 2	<i>Propionibacterium acnes</i>	<i>Candida albicans</i>
Cytomegalovirus	Human Papillomavirus	<i>Staphylococcus aureus</i>	
Dengue virus types 1, 2, 3, and 4	Influenza Virus A		
Epstein-Barr Virus	Murray Valley encephalitis Virus		
FSME Virus (strain HYPR)	St. Louis encephalitis Virus		
Hepatitis A Virus	Varicella-Zoster Virus		
Hepatitis B Virus	West Nile Virus		
Human Immunodeficiency Virus-1	Yellow Fever Virus		
Human T-Cell Lymphotropic Virus type 1 and 2	Zika Virus		
Human Herpes Virus type 6			

Analytical specificity – interfering substances

Elevated levels of triglycerides (27.9 - 29.0 g/L), conjugated bilirubin (0.18 - 0.22 g/L), unconjugated bilirubin (0.19 - 0.2 g/L), albumin (57.8 - 60.6 g/L), hemoglobin (1.8 - 2.3 g/L) and human DNA (2 mg/L) in samples were tested in presence and absence of HCV RNA. The tested substances were shown not to interfere with the test performance of cobas® HCV.

Moreover, the presence of markers for the autoimmune diseases systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and antinuclear antibody (ANA) were tested.

In addition, drug compounds listed in Table 15 were tested at three times the C_{max} in presence and absence of HCV RNA.

All potentially interfering substances have been shown to not interfere with the test performance. Negative results were obtained with cobas® HCV for all samples without HCV target and positive results were obtained on all of the samples with HCV target. Furthermore, the mean \log_{10} titer of each of the positive HCV samples containing potentially interfering substances was within $\pm 0.04 \log_{10}$ of the mean \log_{10} titer of the respective positive spike control.

Table 15: Drug compounds tested for interference with the quantitation of HCV RNA by cobas® HCV


Class of drug	Generic drug name	
Immune Modulators	Peginterferon α -2a Peginterferon α -2b	Ribavirin
HIV Entry Inhibitor	Maraviroc	
HIV Integrase Inhibitors	Elvitegravir/Cobicistat	Raltegravir
Non-nucleoside HIV Reverse Transcriptase Inhibitors	Efavirenz Etravirine	Nevirapine Rilpivirine
HIV Protease inhibitors	Atazanavir Darunavir Fosamprenavir Lopinavir	Nelfinavir Ritonavir Saquinavir Tipranavir
HCV Protease Inhibitors	Boceprevir Simeprevir	Telaprevir
Reverse Transcriptase or DNA Polymerase Inhibitors	Abacavir Aciclovir Adefovir dipivoxil Cidofovir Emtricitabine Entecavir Foscarnet	Ganciclovir Lamivudine Sofosbuvir Telbivudine Tenofovir Valganciclovir Zidovudine
Compounds for Treatment of Opportunistic Infections	Azithromycin Clarithromycin Ethambutol Fluconazole Isoniazid	Pyrazinamide Rifabutin Rifampicin Sulfamethoxazole Trimethoprim

Method correlation

Performance evaluation of cobas® HCV compared to the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, v2.0

The performance of cobas® HCV and the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, v2.0 (TaqMan® HCV Test, v2.0) were compared by analysis of serum and EDTA plasma samples from HCV-infected patients. A total of 176 EDTA plasma and 176 serum samples across all HCV genotypes, analyzed in duplicate, were valid and within the quantitation range of both tests. The Deming regression analysis was performed. The mean titer deviation of the samples tested with the two tests was $0.0 \log_{10}$ (95% Confidence Interval: -0.01; 0.01).


The Deming regression results are shown in Figure 6. The symbol * in the figures shows single determination. The color represents the genotype.

Figure 6: Regression analysis of cobas® HCV vs TaqMan® HCV Test, v2.0, EDTA plasma and serum samples

Matrix equivalency – EDTA plasma versus serum

One hundred fourteen paired EDTA plasma and serum samples were analyzed for matrix equivalency. Of these, 59 paired samples were HCV positive samples. The HCV positive samples covered genotypes 1 to 5 across the linear range.

The mean titer deviation measured for the matching EDTA plasma and serum samples was $0.04 \log_{10}$ (95% Confidence Interval: 0.00; 0.08) (Figure 7).

Figure 7: Matrix equivalency performance between EDTA plasma and serum

Whole system failure

The whole system failure rate for cobas® HCV was determined by testing 100 replicates of EDTA plasma spiked with HCV target. These samples were tested at a target concentration of approximately $3 \times \text{LLoQ}$ (45.0 IU/mL).

The results of this study determined that all replicates were valid and positive for the HCV resulting in a whole system failure rate of 0.0%. The two-sided 95% exact confidence interval was 0.0% for the lower bound and 3.6% for the upper bound [0.0%: 3.6%].

Cross contamination

The cross-contamination rate for cobas® HCV was determined by testing 230 replicates of HCV-negative EDTA-plasma samples and 235 replicates of a high titer HCV sample at $1.8\text{E}+08$ IU/mL. In total, five runs were performed with positive and negative samples in a checkerboard configuration.

Two hundred twenty-nine of 230 replicates of the negative samples were valid and detected negative, resulting in a cross-contamination rate of 0.0% with a one-sided 95% confidence interval of 1.3%.

Clinical performance evaluation

Key performance characteristics

The data for the Clinical utility and Diagnostic utility studies were transferred from the **cobas**® 6800/8800 HCV Canadian package insert (06997732190) and it was performed on **cobas**® 6800/8800 analyzers.

This study²⁹ shows that the concordance between **cobas**® 6800/8800 HCV and **cobas**® 4800 HCV was very high, exceeding 97% for determining results as “detectable” or “undetectable” in a large number of clinical samples.

Clinical utility

The study was designed to evaluate the ability of the assay to predict clinical outcome.

Treatment Plan 1 included four treatment regimens, containing a combination of direct acting antiviral (DAA) compounds with or without pegIFN/RBV. Subjects were infected with HCV genotype 1 and were partial or null responders during a previous course of pegIFN/RBV combination therapy.

Treatment Plan 2 included subjects infected with genotype 2 or 3, who were treatment naïve and received a course of pegIFN/RBV combination therapy.

Testing with **cobas**® HCV was performed at four sites. Three sites were equipped with one **cobas**® 6800 System. Two sites were equipped with **cobas**® 8800 System. One site tested on both the **cobas**® 6800 and 8800 Systems. Three kit lots of reagents were used in the study; each sample was tested with one kit lot.

Table 16 below shows the demographic and baseline characteristics of subjects whose samples were tested on the **cobas**® 6800 and the **cobas**® 8800 Systems.

The demographic distribution of the subjects in this study was consistent with that of chronic HCV patients in the US,²³ the majority being male, over 40 years of age, and infected with HCV genotype 1. Subjects with HCV genotypes 1, 2, and 3 were enrolled. HCV infection with genotypes 4, 5, and 6 is rare in the US.

Table 16: Demographics and baseline characteristics of subjects for the cobas® 6800 and cobas® 8800 Systems

Characteristics	cobas® 6800 System		cobas® 8800 System	
	Statistics	Subjects	Statistics	Subjects
Total	N	401	N	353
Treatment Plan				
1	n (%)	307 (76.6%)	n (%)	287 (81.3%)
2	n (%)	94 (23.4%)	n (%)	66 (18.7%)
Age Category (years)				
< 40	n (%)	90 (22.4%)	n (%)	81 (22.9%)
≥ 40	n (%)	311 (77.6%)	n (%)	272 (77.1%)
Age (years)				
	Mean ± SD	49 ± 11.1	Mean ± SD	49 ± 11.2
	Median	52	Median	52
	Range	20 - 76	Range	20 - 71
Gender				
Male	n (%)	276 (68.8%)	n (%)	245 (69.4%)
Female	n (%)	125 (31.2%)	n (%)	108 (30.6%)
Race / Ethnicity				
Asian	n (%)	3 (0.7%)	n (%)	2 (0.6%)
African American	n (%)	13 (3.2%)	n (%)	12 (3.4%)
White/Caucasian	n (%)	357 (89.0%)	n (%)	318 (90.1%)
Other	n (%)	28 (7.0%)	n (%)	21 (5.9%)
Genotype				
1A	n (%)	174 (43.4%)	n (%)	159 (45.0%)
1B	n (%)	133 (33.2%)	n (%)	128 (36.3%)
Overall 1	n (%)	307 (76.6%)	n (%)	287 (81.3%)
2	n (%)	31 (7.7%)	n (%)	22 (6.2%)
3	n (%)	63 (15.7%)	n (%)	44 (12.5%)
Overall Non-1	n (%)	94 (23.4%)	n (%)	66 (18.7%)
Baseline HCV RNA (log₁₀ IU/mL)				
	Mean ± SD	6.32 ± 0.58	Mean ± SD	6.33 ± 0.56
	Median	6.41	Median	6.41
	Range	2.57 - 7.52	Range	2.77 - 7.52
HCV RNA Category at Baseline				
< 400,000 IU/mL	n (%)	36 (9.0%)	n (%)	32 (9.1%)
≥ 400,000 IU/mL	n (%)	363 (90.5%)	n (%)	304 (86.1%)
Missing	n (%)	2 (0.5%)	n (%)	17 (4.8%)

HCV = hepatitis C virus; RNA = ribonucleic acid; SD = standard deviation.

Prediction of response to antiviral therapy

Assay performance characteristics have been established for individuals treated with certain DAA regimens. No information is available on the assay's predictive value when other DAA combination therapies are used.

Definitions:

- Week 2 viral load (VL) = HCV RNA < LLoQ = LoD = 15 IU/mL at Week 2 of antiviral therapy
- Week 2 VL: HCV RNA < LoD = LLoQ of 15 IU/mL
- Week 4 VL: HCV RNA < LLoQ at Week 4 of antiviral therapy
- Week 8 VL: HCV RNA < LLoQ at Week 8 of antiviral therapy
- Week 12 VL: Either at least a 2 log₁₀ drop in HCV RNA level compared to baseline or HCV RNA < LLoQ at Week 12 of antiviral therapy
- Week 24 VL [End of Treatment(EOT)]: HCV RNA < LLoQ at Week 24 of antiviral therapy.
- Sustained Virologic Response (SVR)12: HCV RNA < LLoQ at Week 12 after completion of antiviral therapy measured with an independent HCV RNA test.

Predictive value of VR to success of antiviral therapy

In this study, the positive predictive value (PPV) for Week 4 VL to predict SVR12 was 78.1% (95% CI: 72.7 to 82.8%) in genotype 1 subjects and 84.7% (95% CI: 73.5 to 91.8%) in subjects with non-1 genotypes (Table 17). Therefore, VR at Week 4 measured by cobas® HCV was a useful predictor of SVR 12.

For Treatment Plan 1, as a representative of a DAA containing regimen, a Week 12 VL or Week 24 VL on cobas® HCV predicts SVR12 in genotype 1 subjects, with PPVs of 77.0% and 78.6%, respectively. The absence of Week 12 VL or Week 24 VL predicts non-response, with negative predictive values (NPV)s of 87.5% and 100%, respectively (Table 17). Additional analysis of Week 2 VL to predict SVR12 shows a PPV of 79.4% but a low NPV of 29.9%. The most recent AASLD guidelines from 2014 have not included any earlier virologic decline assessments than Week 4.²⁴

In Treatment Plan 2, Week 12 VL using cobas® HCV in genotype 2 and 3 was predictive of SVR12, with a PPV of 75.3%. Due to the rarity of non-response, absence of Week 12 VL is not a useful measure of outcome in this population. The NPV was 50% and the number of non-responders was small in this study (Table 17).

Overall, this study demonstrated the clinical utility of cobas® HCV and the continued value of the assessment of Week 4, Week 12, and Week 24 HCV RNA responses in patients undergoing treatment for chronic HCV infection.

Table 17: Probability of achieving Sustained Virological Response (SVR12) given virologic response (< 15 IU/mL) at a specific on-treatment visit for the cobas® 6800 System

Treatment Plan	Genotype	On-Treatment Visit	Eligible Subjects	PPV (%)		NPV (%)		OR
				Estimate (95% CI)	n / N	Estimate (95% CI)	n / N	Estimate (95% CI)
1	1	Week 2	290	79.4 (71.5, 85.5)	100 / 126	29.9 (23.4, 37.3)	49 / 164	1.64 (0.95, 2.83)
		Week 4	290	78.1 (72.7, 82.8)	200 / 256	50.0 (34.1, 65.9)	17 / 34	3.57 (1.71, 7.45)
		Week 8	285	76.8 (71.5, 81.4)	212 / 276	66.7 (35.4, 87.9)	6 / 9	6.63 (1.61, 27.24)
		Week 12	286	77.0 (71.7, 81.5)	214 / 278	87.5 (52.9, 97.8)	7 / 8	23.41 (2.83, 193.80)
		Week 24	282	78.6 (73.4, 83.0)	217 / 276	100.0 (61.0, 100.0)	6 / 6	47.52 (2.64, 855.66)
2	Non-1	Week 4	82	84.7 (73.5, 91.8)	50 / 59	47.8 (29.2, 67.0)	11 / 23	5.09 (1.72, 15.04)
		Week 12	83	75.3 (64.9, 83.4)	61 / 81	50.0 (9.5, 90.5)	1 / 2	3.05 (0.18, 51.04)

Note: Positive Predictive Value (PPV) = $TP / (TP + FP)$ or the probability of being an SVR12 given the subject was a viral responder at a specific visit. SVR12 is achieved if the subject has HCV RNA < 15 IU/mL at 12 weeks after the last dose.

Negative Predictive Value (NPV) = $TN / (FN + TN)$ or the probability of not being an SVR12 given the subject was not a viral responder at a specific visit.


Odds Ratio (OR) = $(TP \cdot TN) / (FP \cdot FN)$

CI = confidence interval; FN = false negative; FP = false positive; HCV = hepatitis C virus; SVR12 = sustained virological response 12 weeks after the last dose; TN = true negative; TP = true positive.

Comparison between cobas® 6800 and cobas® 8800 Systems – clinical utility

An identical sample set was tested for the clinical utility of cobas® HCV on the cobas® 8800 System. The systems demonstrate highly correlated performance that were not significantly different. Figure 8 below show a Deming regression plots of VLs (\log_{10} IU/mL) greater than 15 IU/mL at all applicable time points on treatment.

Figure 8: Deming linear regression plot of viral loads (\log_{10} IU/mL) from Baseline, Week 2 and Week 4 (cobas® 6800 System versus cobas® 8800 System)



CI = confidence interval.

Diagnostic utility

The study was designed to evaluate the ability of the assay to correctly diagnose anti-HCV positive subjects with active HCV infection.

Table 18 below show the demographic and clinical characteristics of subjects whose samples were tested on the cobas® 6800 System and cobas® 8800 System.

Table 18: Demographic and clinical characteristics by system (HCV antibody positive subjects)

Characteristics	cobas® 6800 System	cobas® 8800 System
Total, N	235	230
Clinical Condition		
HCV Antibody Positive^a, n(%)		
HCV RNA Positive	154 (65.5%)	150 (65.2%)
HCV RNA Negative	81 (34.5%)	80 (34.8%)
Age (years)		
Mean ± SD	48 ± 11.9	49 ± 11.9
Median	50	50
Range	20 - 88	20 - 88
Gender, n(%)		
Male	132 (56.2%)	127 (55.2%)
Female	103 (43.8%)	103 (44.8%)
Race, n(%)		
Black / African-American	49 (20.9%)	48 (20.9%)
White / Caucasian	183 (77.9%)	179 (77.8%)
Other	3 (1.3%)	3 (1.3%)
Risk Factor, n(%)		
Baby Boomers (Born: 1945--1965) only	114 (48.5%)	112 (48.7%)
IVD Users only	22 (9.4%)	22 (9.6%)
Baby Boomers and IVD Users	23 (9.8%)	22 (9.6%)
Undisclosed, HCV antibody positive*	76 (32.3%)	74 (32.2%)

^a VERSANT HCV Test result was used to determine HCV RNA status. For subjects whose VERSANT HCV Test result was not available, the APTIMA HCV Test result was used. If both Versant and Aptima results were not available then COBAS® AMPLICOR® HCV Test, v2.0 result was used.

* Undisclosed includes those subjects for whom both the risk factors are either missing or 'No', or those for whom one risk factor is missing and the other has a value of 'No'.

APTIMA = Aptima HCV RNA Qualitative Assay; HCV = hepatitis C Virus; IVD = Intravenous Drug Use.

SD = standard deviation; VERSANT= VERSANT HCV RNA Qualitative Assay.

The sensitivity of cobas® HCV was evaluated in subjects who had previous exposure to HCV and tested positive for HCV antibody on both cobas® 6800 /8800 Systems (Table 19).

According to current AASLD Guidelines¹¹, an FDA-approved quantitative or qualitative NAT with a detection level of 25 IU/mL or lower should be used to detect HCV RNA.

The agreement of cobas® HCV with patient infection status was determined using a cutoff of < 25 IU/mL to define the absence of active HCV infection (Table 19).

Table 19: Agreement of cobas® HCV on the cobas® 6800 and the cobas® 8800 System with the patient infection status using a cutoff of 25 IU/mL

cobas® HCV	Patient Infected Status (PIS)					
	cobas® 6800 System			cobas® 8800 System		
	HCV Positive	HCV Negative	Total	HCV Positive	HCV Negative	Total
HCV RNA Detected Above 25 IU/mL	152	0	152	149	1	150
HCV RNA not Detected or detected below 25 IU/mL	0	81	81	0	79	79
Total	152	81	233	149	80	229
Positive Percent Agreement (95% score CI)	100.0 % (97.5, 100.0)	NA	NA	100.0 % (97.5, 100.0)	NA	NA
Negative Percent Agreement (95% score CI)	NA	100.0 % (95.5, 100.0)	NA	NA	98.8 % (93.3, 99.8)	NA

Note: Only valid results from cobas® HCV among the HCV Antibody Positive specimens are included in this table.

CI = confidence interval; cobas® HCV = cobas® HCV for use on the cobas® 6800/8800 systems; HCV = hepatitis C virus; NA = not applicable.

This study demonstrates the clinical utility of cobas® HCV to correctly diagnose subjects with ongoing active HCV RNA infection and to distinguish them from subjects with inactive infections in a population with prior exposure to HCV (HCV antibody-positive serology).

Cross-reactivity in subjects with non-HCV related liver disease

The cross-reactivity of cobas® HCV was evaluated with specimens that represented a variety of liver diseases for which active HCV infection was not the underlying cause. cobas® HCV demonstrated the ability to determine absence of active HCV infection in subjects with a range of liver diseases due to causes other than HCV (Table 20, Table 21, Table 22).

Table 20: Demographic and clinical characteristics by system

Characteristics	cobas® 6800 System	cobas® 8800 System
Total, N	247	181
Clinical Condition		
HCV RNA Negative, n(%)		
Alcoholic Liver Disease	33 (13.4%)	20 (11.0%)
Autoimmune Hepatitis	37 (15.0%)	32 (17.7%)
Chronic HBV	30 (12.1%)	30 (16.6%)
Fatty Liver Disease	66 (26.7%)	38 (21.0%)
Non-Alcoholic Steatohepatitis (NASH)	41 (16.6%)	30 (16.6%)
Nonspecific Cirrhosis	6 (2.4%)	3 (1.7%)
Primary Billiary Cirrhosis	33 (13.4%)	28 (15.5%)
Unknown ^a	1 (0.4%)	
Age (years)		
Mean ± SD	54 ± 13.1	54 ± 13.5
Median	56	56
Range	20 - 81	20 - 81
Gender, n(%)		
Male	71 (28.7%)	44 (24.3%)
Female	104 (42.1%)	74 (40.9%)
Unknown	72 (29.1%)	63 (34.8%)
Race, n(%)		
Asian	11 (4.5%)	1 (0.6%)
Black / African-American	13 (5.3%)	11 (6.1%)
White / Caucasian	70 (28.3%)	48 (26.5%)
Other	7 (2.8%)	1 (0.6%)
Unknown	146 (59.1%)	120 (66.3%)
Baby Boomers (Born: 1945-1965), n(%)		
Yes	80 (32.4%)	63 (34.8%)
No	64 (25.9%)	53 (29.3%)
Undisclosed	103 (41.7%)	65 (35.9%)

Table 21: Number of HCV RNA negative samples on the cobas® 6800 System with non HCV-related liver diseases within test result categories by clinical condition

Clinical Condition	Number of Valid Tests						Specificity ^a % (95% CI) ^b
	Target Not Detected	< 1.50E+01 IU/mL	1.50E+01 ≤ x < 2.50E+01 IU/mL	2.50E+01 ≤ x ≤ 1.00E+08 IU/mL	> 1.00E+08 IU/mL	Total	
Alcoholic Liver Disease	33	0	0	0	0	33	100.0 (89.4, 100.0)
Autoimmune Hepatitis	37	0	0	0	0	37	100.0 (90.5, 100.0)
Chronic HBV	30	0	0	0	0	30	100.0 (88.4, 100.0)
Fatty Liver Disease	66	0	0	0	0	66	100.0 (94.6, 100.0)
NASH	40	1*	0	0	0	41	97.6 (87.1, 99.9)
Nonspecific Cirrhosis	6	0	0	0	0	6	100.0 (54.1, 100.0)
Primary Billiary Cirrhosis	33	0	0	0	0	33	100.0 (89.4, 100.0)
Total	245	1*	0	0	0	246	99.6 (97.8, 100.0)

Note: Only valid results from cobas® HCV among the HCV Antibody negative specimens (non-HCV-related liver disease) are included in this table.

The single subject with Hepatic Steatosis liver disease was excluded.

^a Clinical Specificity: percentage of number of RNA negative result to the total number of HCV Antibody negative specimens among valid test results.

^b 95% CI: 95% exact confidence interval.

* Sample reported <LLOQ, HCV RNA detected at ~ 1.5 IU/mL.

CI = confidence interval; HBV = hepatitis B virus; HCV = hepatitis C virus; NASH = non-alcoholic steatohepatitis.

Table 22: Number of HCV RNA negative samples on the **cobas**® 8800 System with non HCV-related liver diseases within test result categories by clinical condition

Clinical Condition	Number of Valid Tests						Specificity ^a % (95% CI) ^b
	Target Not Detected	< 1.50E+01 IU/mL	1.50E+01 ≤ x < 2.50E+01 IU/mL	2.50E+01 ≤ x ≤ 1.00E+08 IU/mL	> 1.00E+08 IU/mL	Total	
Alcoholic Liver Disease	20	0	0	0	0	20	100.0 (83.2, 100.0)
Autoimmune Hepatitis	32	0	0	0	0	32	100.0 (89.1, 100.0)
Chronic HBV	30	0	0	0	0	30	100.0 (88.4, 100.0)
Fatty Liver Disease	38	0	0	0	0	38	100.0 (90.7, 100.0)
NASH	30	0	0	0	0	30	100.0 (88.4, 100.0)
Nonspecific Cirrhosis	3	0	0	0	0	3	100.0 (29.2, 100.0)
Primary Biliary Cirrhosis	28	0	0	0	0	28	100.0 (87.7, 100.0)
Total	181	0	0	0	0	181	100.0 (98.0, 100.0)

Note: Only valid results from the **cobas**® HCV among the HCV Antibody negative specimens (non-HCV-related liver disease) are included in this table.

^a Clinical Specificity: percentage of number of RNA negative result to the total number of HCV Antibody negative specimens among valid test results.

^b 95% CI: 95% exact confidence interval.

CI = confidence interval; HBV = hepatitis B virus; HCV = hepatitis C virus; NASH = non-alcoholic steatohepatitis.

When highly sensitive real-time quantitative PCR assays such as **cobas**® HCV are used to aid in the diagnoses of HCV infection, a cut-off of 25 IU/mL should be applied to distinguish between non-active and active HCV infection. The HCV RNA concentration, together with other markers of active liver disease, need to be evaluated if antiviral treatment is being considered.²⁴

Comparison between **cobas**® 6800 and **cobas**® 8800 Systems for diagnosis

A subset of the samples was tested for confirmation of active HCV infection of **cobas**® HCV on the **cobas**® 8800 System. The specificity of **cobas**® HCV, in a variety of liver diseases for which active HCV infection was not the underlying cause, was also 100%. The agreement of **cobas**® HCV on the **cobas**® 8800 System with patient infection status, using a cutoff of < 25 IU/mL to define absence of active HCV infection, was 99.6%. These results indicate that the **cobas**® 6800 and **cobas**® 8800 Systems are comparable for diagnosis of active HCV using **cobas**® HCV.

Conclusion

cobas® HCV can quantitate the level of HCV RNA to assess treatment and predict response to antiviral therapy. The results of this study demonstrate the clinical utility of this test for determining early on-treatment response to therapy in the management of patients with chronic HCV infection.

Additionally, **cobas**® HCV can be used as an aid in the diagnosis of active HCV infection in HCV-antibody-positive patients.

Additional information





















































Key assay features

Sample type	EDTA plasma, serum
Sample processing volume	400 µL or 200 µL
Analytical sensitivity	9.2 IU/mL (400 µL) 15.3 IU/mL (200 µL)
Linear range	400 µL: 15.0 IU/mL – 1.0E+08 IU/mL 200 µL: 25.0 IU/mL – 1.0E+08 IU/mL
Specificity	99.5% (one-sided 95% confidence interval: 98.7%)
Genotypes detected	HCV genotypes 1-6

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 23: Symbols used in labeling for Roche PCR diagnostic products

 Age/DOB	Age or Date of Birth		Device not for near-patient testing		QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.
	Ancillary Software		Device not for self-testing		
	Assigned Range (copies/mL)		Distributor <i>(Note: The applicable country/region may be designated beneath the symbol)</i>		Serial number
	Assigned Range (IU/mL)		Do not re-use		Site
	Authorized representative in the European Community		Female		Standard Procedure
	Barcode Data Sheet		For IVD performance evaluation only		Sterilized using ethylene oxide
	Batch code		Global Trade Item Number		Store in dark
	Biological risks		Importer		Temperature limit
	Catalogue number		In vitro diagnostic medical device		Test Definition File
	CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an in vitro diagnostic medical device		Lower Limit of Assigned Range		This way up
	Collect date		Male		Ultrasensitive Procedure
	Consult instructions for use		Manufacturer		Unique Device Identifier
	Contains sufficient for <n> tests		Negative control		Upper Limit of Assigned Range
	Content of kit		Non-sterile		Urine Fill Line
	Control		Patient Name		For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.
	Date of manufacture		Patient number		Use-by date
	Device for near-patient testing		Peel here		
	Device for self-testing		Positive control		
			QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.		

Technical Support

For technical support (assistance) please reach out to your local affiliate:
https://www.roche.com/about/business/roche_worldwide.htm

Manufacturer

Table 24: Manufacturer



Manufactured in the United States

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany
www.roche.com

Made in USA

Trademarks and patents

<https://diagnostics.roche.com/us/en/about-us/patents>

Copyright

©2024 Roche Molecular Systems, Inc.



References

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*. 1989;244(4902):359-362.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med*. 2006;144(10):705-714.
3. Rustgi VK. The epidemiology of hepatitis C infection in the United States. *J Gastroenterol*. 2007;42(7):513-521.
4. Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 2001;345(1):41-52.
5. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med*. 1998;339(21):1485-1492.
6. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med*. 1998;339(21):1493-1499.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*. 2001;358(9286):958-965.
8. Fried MW, Shiffman ML, Reddy KR, al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*. 2002;347(13):975-982.
9. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*. 2004;140(5):346-355.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Disease (AASLD) Practice Guidelines. Diagnosis, Management, and Treatment of Hepatitis C: An Update *Hepatology*. 2009;49(4):1335-1374.
11. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology*. 2011;54(4):1433-1444.
12. Poordad F, McCone J, Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med*. 2011;364(13):1195-1206.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med*. 2011;364(25):2405-2416.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med*. 2011;364(13):1207-1217.
15. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med*. 2011;364(25):2417-2428.
16. Lawitz E, Mangia A, Wyles D, t al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med*. 2013;368(20):1878-1887.
17. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med*. 2013;368(20):1867-1877.

18. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. *N Engl J Med.* 2013;368(20):1907-1917.
19. Rutter K, Hofer H, Beinhardt S, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-alpha2a/ribavirin in combination with a direct-acting anti-viral. *Aliment Pharmacol Ther.* 2013;38(2):118-123.
20. European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C 2014. Available at: http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014.
21. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. *Clin Liver Dis.* 2003; 7:127–7137.
22. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. *Gene.* 1990;93:125-128.
23. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. *Nature.* 1995;373:487-493.
24. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. *Cell.* 1995;80:869-878.
25. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. *Biotechnology (NY).* 1992;10:413-417.
26. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. *Genome Res.* 1996;6:986-994.
27. Center for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health HHS Publication No. (CDC) 21-1112, revised December 2009.
28. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4:Wayne, PA;CLSI, 2014.
29. Vermehren J, Stelzi E, Massoumy B, et al. Multicenter comparison study of both analytical and clinical performance across four Roche Hepatitis C virus RNA assays utilizing different platforms. *J. Clin. Microbiol.* -2017;55:1131-1139.

Document revision

Document Revision Information	
Doc Rev. 4.0 02/2024	<p>Updated Lysis Kits 2 hazard information.</p> <p>Updated the harmonized symbol page.</p> <p>Added Technical support section.</p> <p>Updated to current economic operators.</p> <p>Added Made in statement.</p> <p>Updated cobas® branding.</p> <p>Updated Trademarks and patents section, including the link.</p> <p>Please contact your local Roche Representative if you have any questions.</p>
Doc Rev. 5.0 08/2024	<p>Updated Wash Buffer kits hazard information.</p> <p>Updated the harmonized symbol page.</p> <p>Removed Rx Only from front page.</p> <p>Please contact your local Roche Representative if you have any questions.</p>